ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017
Human Papillomavirus Vaccination Rates in Young Cancer Survivors.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 57 citations in OpenAlex.
- Trial
- Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial.The Lancet. Child & adolescent health · 2022Trial
- Article
- Human papillomavirus vaccine uptake among adolescent survivors of hematopoietic stem cell transplant.Journal of cancer survivorship : research and practice · 2026Article
- Examining HPV vaccination coverage among childhood, adolescent, and young adult cancer survivors: a report from the St. Jude Lifetime Cohort study.Journal of cancer survivorship : research and practice · 2026Article
- Gynaecological follow-up of adolescent and young adult cancer survivors: a comparative cohort study.BMJ open · 2025Article
- Human papillomavirus vaccination among childhood cancer survivors: A scoping review.Human vaccines & immunotherapeutics · 2025Article
- Human papillomavirus-related squamous cell carcinomas after blood or marrow transplantation-a Blood or Marrow Transplant Survivor Study report.Journal of the National Cancer Institute · 2025Article
- Article
- Implementation barriers and considerations for recommending and administering the human papillomavirus (HPV) vaccination in oncology settings.Journal of cancer survivorship : research and practice · 2024Article
- Article
- Vaccination uptake among post-treatment cancer survivors: A multi-vaccine scoping review.Vaccine · 2024Article
- Review
- Examining the Barriers and Opportunities for Human Papillomavirus Vaccine Delivery in Cancer Care Settings: A Mixed-Methods Study.Cancer prevention research (Philadelphia, Pa.) · 2023Article
- Pediatric hematology and oncology physician and nurse practitioner views of the HPV vaccine and barriers to administration.Human vaccines & immunotherapeutics · 2023Article
- Drivers of COVID-19 Vaccine Intent Among Survivors of Adolescent and Young Adult Cancer: a Mixed Method Study.Journal of cancer education : the official journal of the American Association for Cancer Education · 2023Article
- HPV Vaccination Initiation and Completion Among Pediatric, Adolescent, and Young Adult Cancer Survivors and a Comparison Population Sample Receiving Primary Care.Journal of pediatric hematology/oncology · 2023Article
- Gaps in knowledge about the vaccine coverage of immunocompromised children: a scoping review.Human vaccines & immunotherapeutics · 2022Article
- Childhood cancer survivorship in China: An overview of the past two decades.Cancer medicine · 2022Review
- Human papillomavirus vaccination uptake among childhood cancer survivors in Western New York.Pediatric blood & cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Funding
Abstract
Purpose: Cancer survivors are at high risk for human papillomavirus (HPV)-related morbidities; we estimated the prevalence of HPV vaccine initiation in cancer survivors versus the US population and examined predictors of noninitiation. Methods: Participants included 982 cancer survivors (9 to 26 years of age; 1 to 5 years postcompletion of therapy); we assessed HPV vaccine initiation, sociodemographic and clinical characteristics, and vaccine-specific health beliefs; age-, sex-, and year-matched US population comparisons were from the National Immunization Survey-Teen and the National Health Interview Survey (2012-2015). Results: The mean age at the time of the study was 16.3 ± 4.7 years; the mean time off therapy was 2.7 ± 1.2 years; participants were 55% male and 66% non-Hispanic white; 59% had leukemia/lymphoma. Vaccine initiation rates were significantly lower in cancer survivors versus the general population (23.8%; 95% CI, 20.6% to 27.0% v 40.5%; 95% CI, 40.2% to 40.7%; P < .001); survivors were more likely to be HPV vaccine-naïve than general population peers (odds ratio [OR], 1.72; 95% CI, 1.41 to 2.09; P < .001). Initiation in adolescent survivors (ages 13 to 17 years) was 22.0% (95% CI, 17.3% to 26.7%), significantly lower than population peers (42.5%; 95% CI, 42.2% to 42.8%; P < .001). Initiation in young adult survivors and peers (ages 18 to 26 years) was comparably low (25.3%; 95% CI, 20.9% to 29.7% v 24.2%; 95% CI, 23.6% to 24.9%). Predictors of noninitiation included lack of provider recommendation (OR, 10.8; 95% CI, 6.5 to 18.0; P < .001), survivors' perceived lack of insurance coverage for HPV vaccine (OR, 6.6; 95% CI, 3.9 to 11.0; P < .001), male sex (OR, 2.9; 95% CI, 1.7 to 4.8; P < .001), endorsement of vaccine-related barriers (OR, 2.7; 95% CI, 1.6 to 4.6; P < .001), and younger age (9 to 12 years; OR, 3.7; 95% CI, 1.8-7.6; P < .001; comparison, 13 to 17 years). Conclusion: HPV vaccine initiation rates in cancer survivors are low. Lack of provider recommendation and barriers to vaccine receipt should be targeted in vaccine promotion efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.